David Sackel, MD
Ophthalmology · Atlanta, GANPI 1235459512
Payments from drug & device makers
Across 623 payments — averaging $131.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$53K
- Alcon$9K
- Glaukos Corporation$4K
- Harrow Eye, LLC$2K
- Sight Sciences, Inc.$2K
- Biotissue Holdings Inc.$2K
- plus $9K from 25 others
What the payments were for
- Consulting fees$50,24961%
- Speaking & faculty fees$3,3394%
- Travel & lodging$2,3293%
- Food & beverage$24,40030%
- Education$5001%
- Gifts$190%
- Other$9301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 114 | $53,491 |
| Alcon | 221 | $8,853 |
| Glaukos Corporation | 67 | $4,101 |
| Harrow Eye, LLC | 16 | $2,273 |
| Sight Sciences, Inc. | 5 | $2,143 |
| Biotissue Holdings Inc. | 19 | $1,914 |
| Carl Zeiss Meditec USA, Inc. | 6 | $1,341 |
| Lensar, Inc. | 1 | $1,300 |
| Sun Pharmaceutical Industries Inc. | 43 | $1,261 |
| AbbVie(2 entities) | 20 | $725 |
| Carl Zeiss Meditec, Inc. | 6 | $515 |
| Coopervision Inc. | 3 | $514 |
| Rxsight Inc | 9 | $508 |
| Bausch & Lomb Americas Inc. | 18 | $428 |
| Eyevance Pharmaceuticals LLC | 9 | $351 |
| Kala Pharmaceuticals, Inc. | 8 | $330 |
| Eyepoint US, Inc. | 3 | $270 |
| Tarsus Pharmaceuticals, Inc. | 5 | $233 |
| Oyster Point Pharma, Inc. | 5 | $218 |
| Shire North American Group Inc | 4 | $190 |
| Novartis | 9 | $178 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $158 |
| Amgen(2 entities) | 8 | $154 |
| Dompe US, Inc. | 5 | $83 |
| Akorn Operating Company LLC | 3 | $66 |
| Thea Pharma Inc. | 2 | $45 |
| Recordati_rare_diseases_inc. | 2 | $43 |
| Leadiant Biosciences, Inc. | 1 | $21 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CATALYS SYSTEM$36,540
- Tecnis Symfony IOL$2,463
- VEVYE$1,924
- OMNI(R) SURGICAL SYSTEM (US)$1,800
- SION SURGICAL INSTRUMENT$1,800
- Tecnis IOL$1,772
- Clareon$1,425
- LENSAR LASER SYSTEM$1,300
- KXL System$1,213
- LenSx$1,150
- LUMERA 700$1,099
- Prokera$974
- Photrexa$949
- VERITAS Vision System$561
- CE-marked KXLA system$541
- MiSight Contact Lens$500
- AmnioGraft$393
- AcrySof IQ PanOptix$375
- Clareon PanOptix Pro$361
- Tecnis Simplicity$360
How this compares
$81,766 in reported general payments places this provider in the 90th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 57 | $71,221 |
| RestasisCyclosporine | 54 | $60,226 |
| CequaCyclosporine | 27 | $31,789 |
| MieboPerfluorohexyloctane/Pf | 20 | $20,320 |
| VevyeCyclosporine | 18 | $19,219 |
| Prednisolone Acetate | 360 | $15,316 |
| LumiganBimatoprost | 21 | $12,451 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $9,152 |
| Cyclosporine | 17 | $8,232 |
| Loteprednol Etabonate | 37 | $6,417 |
| MoxifloxacinMoxifloxacin Hcl | 239 | $4,858 |
| ValacyclovirValacyclovir Hcl | 79 | $2,549 |
| Latanoprost | 157 | $2,474 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $1,873 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 38 | $1,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $428 | $91,54177 claims |
| AbbVieRestasis, Lumigan, Combigan | $725 | $81,829104 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,261 | $31,78927 claims |
| Harrow Eye, LLCVevye | $2,273 | $19,21918 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $158 | $6,41737 claims |
| Eyevance Pharmaceuticals LLCFlarex | $351 | $1,36911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Atlanta
- Douglas DayAtlanta$1.1M
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Atul SharmaAtlanta$193K
- Chris BergstromAtlanta$139K
- Anastasios CostaridesAtlanta$137K
- Evan SchoenbergAtlanta$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.